logo
As US & UK cut funds to Gavi, millions risk losing access to vaccines

As US & UK cut funds to Gavi, millions risk losing access to vaccines

First Post7 hours ago

As the United States and United Kingdom have cut billions in funds to Gavi, the global vaccination partnership, millions of people across the world are set to lose access to affordable vaccines and hundreds of thousands are at the risk of dying. read more
A woman holds her baby as she receives a shot of the Johnson & Johnson vaccine against the coronavirus disease (COVID-19) in the Mavrovouni camp on Lesbos, Greece. (Alkis Konstantinidis/Reuters)
The United States and the United Kingdom have announced cuts to their donations to Gavi, the global vaccination partnership, putting millions across the world at the risk of losing access to affordable vaccines.
While American cuts are rooted in the anti-vaccine stance of the Donald Trump administration, British cuts are a result of diversion of funds from foreign aid towards defence in the wake of the increasing security threats from the likes of Russia and China.
STORY CONTINUES BELOW THIS AD
US Health Secretary Robert F Kennedy Junior has announced the administration will cut around $300 million in annual donations to Gavi, according to Reuters.
The UK has slashed its donations annual contribution to Gavi for the next five years from $438.4 million to $342.5 million, according to The Daily Telegraph.
Estimates have said that millions of people across the world are at the risk of losing access affordable vaccines and hundreds of thousands are at the risk of dying as a result of cuts.
350,000 children at risk of dying, says estimate
Gavi serves some of the poorest people of the world and they are bound to be hit the hardest.
The British cuts alone will threaten 23 million child vaccinations over the next five years and potentially cause 350,000 additional deaths, The Telegraph reported the ONE campaign's estimate as saying.
Gavi has been distributing vaccines for diseases like HPV, malaria, yellow fever, COVID-19, Ebola, measles, and typhoid, in some of the poorest communities of the world. It relies on support from countries and philanthropies.
British International Development Minister Baroness Jenny Chapman told The Telegraph that the cuts are a result of some 'really tough choices' the government had to make.
'We've had to make some really tough choices. But we've decided as a government that we want to invest in defence, because that's the world we are in When we cut the aid budget, we knew we'd have to cut things that are globally good. Gavi would be something it would be great to put more money into in future and I hope we can, but for today this is a good pledge from the UK,' said Chapman.
STORY CONTINUES BELOW THIS AD
China to gain at cost of US & UK
The US vaccine aid cuts are part of the broader foreign aid cuts under the Trump administration.
The Trump administration has hollowed out the US AID that ran the foreign aid programme and has withdrawn from large parts of the world, compromising healthcare, nutritional, and developmental programmes in some of the most vulnerable communities in the world.
The US withdrawal from the world, particularly in the poor and developing parts of the world, will create a vacuum that China will rush to fill in, making foreign aid cuts a self-goal by Trump, Tej Pratap Singh, a scholar of China at the Department of Political Science, Banaras Hindu University, previously told Firstpost.
Humanitarian operations are instruments to peddle soft power the world over and the shutting down of humanitarian operations anywhere is a self-goal, said Singh.
'Developing countries need assistance. If the United States withdraws, China will reach out to these nations and they will be glad to have Chinese support. China has been making inroads in Africa for many years and the US withdrawal is set to increase that. India has been countering Chinese influence in the Global South but countering China needs joint efforts and, in the absence of US involvement, China is set to make good gains,' said Singh.
STORY CONTINUES BELOW THIS AD

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

FDA issues new heart risk warnings for Pfizer, Moderna COVID vaccines - should you be worried?
FDA issues new heart risk warnings for Pfizer, Moderna COVID vaccines - should you be worried?

Economic Times

timean hour ago

  • Economic Times

FDA issues new heart risk warnings for Pfizer, Moderna COVID vaccines - should you be worried?

What's Behind the FDA's New Warning? Who Faces the Highest Risk? Live Events What's Changing in the Vaccine Labels? What's the FDA Doing Next? FAQs (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel The US Food and Drug Administration (FDA) has warned that COVID-19 vaccines, which are manufactured by Pfizer and Moderna, have the potential for cardiac risks, as per a warnings were first proposed in letters, which were sent to both companies in April, providing additional information about the potential risks of myocarditis and/or pericarditis associated with the two vaccines, as reported by the Cardiovascular Business report. Myocarditis and pericarditis have the possibility of leading to long-term heart damage, according to the READ: Meet Trapit Bansal, Meta's new AI superintelligence team hire - Is Meta poaching top talent from OpenAI? FDA's latest update covers Pfizer's Comirnaty vaccine and Moderna's Spikevax vaccine, while both companies had mentioned text about myocarditis and pericarditis in the labelling for these vaccines since 2021, but the FDA wanted more information added to these warnings that specifically mentions the increased risks for young men, as per the Cardiovascular Business READ: After Canada, now US: College graduates face the toughest job market in decades – what's gone wrong? According to the Cardiovascular Business report, the new labeling for both the vaccines is now required to include the following text, as per FDA's latest update:"Based on analyses of commercial health insurance claims data from inpatient and outpatient settings, the estimated unadjusted incidence of myocarditis and/or pericarditis during the period 1 through 7 days following administration of the 2023-2024 Formula of mRNA COVID-19 vaccines was approximately 8 cases per million doses in individuals 6 months through 64 years of age and approximately 27 cases per million doses in males 12 through 24 years of age," as quoted in the label should also include, "Follow-up information on cardiovascular outcomes in hospitalized patients who had been diagnosed with COVID-19 vaccine-associated myocarditis is available from a longitudinal retrospective observational study. Most of these patients had received a two-dose primary series of an mRNA COVID-19 vaccine prior to their diagnosis. In this study, at a median follow-up of approximately 5 months post-vaccination, persistence of abnormal cardiac magnetic resonance imaging (CMR) findings that are a marker for myocardial injury was common. The clinical and prognostic significance of these CMR findings is not known," as quoted by the Cardiovascular Business READ: Top economist warns: US faces a crisis worse than recession — here's what could be coming While, FDA has also emphasised that it plans to keep tracking the safety of COVID-19 vaccines from now on, as per the agency said, 'Continuous monitoring and assessment of the safety of all vaccines, including the mRNA COVID-19 vaccines, is an FDA priority and we remain committed to informing the public when we learn new information about these vaccines,' adding, 'In addition, as part of the approvals of Comirnaty and Spikevax, each manufacturer is required by FDA to conduct a study to assess if there are long-term heart effects in people who have had myocarditis after receiving an mRNA COVID-19 vaccine. These studies are underway,' quoted by the Cardiovascular Business FDA wants the public to have clearer information about rare heart-related risks linked to COVID-19 mRNA vaccines, especially for young men, as per the Cardiovascular Business the FDA continues to support their use, but these warnings are about rare side effects, as per the Cardiovascular Business report.

FDA issues new heart risk warnings for Pfizer, Moderna COVID vaccines - should you be worried?
FDA issues new heart risk warnings for Pfizer, Moderna COVID vaccines - should you be worried?

Time of India

timean hour ago

  • Time of India

FDA issues new heart risk warnings for Pfizer, Moderna COVID vaccines - should you be worried?

The US Food and Drug Administration (FDA) has warned that COVID-19 vaccines, which are manufactured by Pfizer and Moderna, have the potential for cardiac risks, as per a report. What's Behind the FDA's New Warning? These warnings were first proposed in letters, which were sent to both companies in April, providing additional information about the potential risks of myocarditis and/or pericarditis associated with the two vaccines, as reported by the Cardiovascular Business report. Myocarditis and pericarditis have the possibility of leading to long-term heart damage, according to the report. ALSO READ: Meet Trapit Bansal, Meta's new AI superintelligence team hire - Is Meta poaching top talent from OpenAI? by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Play War Thunder now for free War Thunder Play Now Undo Who Faces the Highest Risk? FDA's latest update covers Pfizer's Comirnaty vaccine and Moderna's Spikevax vaccine, while both companies had mentioned text about myocarditis and pericarditis in the labelling for these vaccines since 2021, but the FDA wanted more information added to these warnings that specifically mentions the increased risks for young men, as per the Cardiovascular Business report. ALSO READ: After Canada, now US: College graduates face the toughest job market in decades – what's gone wrong? Live Events What's Changing in the Vaccine Labels? According to the Cardiovascular Business report, the new labeling for both the vaccines is now required to include the following text, as per FDA's latest update: "Based on analyses of commercial health insurance claims data from inpatient and outpatient settings, the estimated unadjusted incidence of myocarditis and/or pericarditis during the period 1 through 7 days following administration of the 2023-2024 Formula of mRNA COVID-19 vaccines was approximately 8 cases per million doses in individuals 6 months through 64 years of age and approximately 27 cases per million doses in males 12 through 24 years of age," as quoted in the report. The label should also include, "Follow-up information on cardiovascular outcomes in hospitalized patients who had been diagnosed with COVID-19 vaccine-associated myocarditis is available from a longitudinal retrospective observational study. Most of these patients had received a two-dose primary series of an mRNA COVID-19 vaccine prior to their diagnosis. In this study, at a median follow-up of approximately 5 months post-vaccination, persistence of abnormal cardiac magnetic resonance imaging (CMR) findings that are a marker for myocardial injury was common. The clinical and prognostic significance of these CMR findings is not known," as quoted by the Cardiovascular Business report. ALSO READ: Top economist warns: US faces a crisis worse than recession — here's what could be coming What's the FDA Doing Next? While, FDA has also emphasised that it plans to keep tracking the safety of COVID-19 vaccines from now on, as per the report. The agency said, 'Continuous monitoring and assessment of the safety of all vaccines, including the mRNA COVID-19 vaccines, is an FDA priority and we remain committed to informing the public when we learn new information about these vaccines,' adding, 'In addition, as part of the approvals of Comirnaty and Spikevax, each manufacturer is required by FDA to conduct a study to assess if there are long-term heart effects in people who have had myocarditis after receiving an mRNA COVID-19 vaccine. These studies are underway,' quoted by the Cardiovascular Business report. FAQs Why is the FDA updating warnings now? The FDA wants the public to have clearer information about rare heart-related risks linked to COVID-19 mRNA vaccines, especially for young men, as per the Cardiovascular Business report. Are Moderna and Pfizer vaccines still considered safe? Yes, the FDA continues to support their use, but these warnings are about rare side effects, as per the Cardiovascular Business report.

Vaccinating India: on zero-dose children
Vaccinating India: on zero-dose children

The Hindu

time3 hours ago

  • The Hindu

Vaccinating India: on zero-dose children

On the bright side, vaccine coverage globally, between 1980 and 2023, doubled for six diseases including measles, polio and tuberculosis. Also, at 75% globally, there has been a sharp fall in the number of zero-dose children — those who have not received the first dose of the diphtheria, tetanus, and pertussis (DTP) vaccine — during the same time period. The number of zero-dose children is a crucial performance marker and an indicator of vaccination coverage inequities. Despite increased immunisation coverage over the decades, in 2023, at 1.44 million, India, according to The Lancet, still had the second largest number of zero-dose children, and is among the eight countries with over 50% of the nearly 16 million zero-dose children globally. Most of the zero-dose children globally are in countries that are conflict-affected or with limited resources for vaccination programmes — India has neither of the two problems. However, about 23 million babies were born in 2023 in India, the highest in the world; in 2024, China, which has the second highest number of newborns globally, reported just 9.5 million newborns. Though the number of zero-dose children is staggering, when seen in the context of the number of newborns in 2023, the percentage of zero-dose children in India is 6.2%. A study in 2021 found that India had sharply reduced the percentage of zero-dose children, from 33.4% in 1992 to 10.1% in 2016. Before the COVID-19 pandemic, the number of zero-dose children was 1.4 million in 2019 but this swelled to 2.7 million in 2021 and then dropped to 1.1 million in 2022 before increasing to 1.44 million in 2023. As in the 2021 study, a large percentage of zero-dose children are in Uttar Pradesh, Bihar, Maharashtra, Rajasthan, Madhya Pradesh, and Gujarat. There is also a relatively high proportion of them in Meghalaya, Nagaland, Mizoram and Arunachal Pradesh. Over the years, the difference in zero-dose children based on gender, caste, and rural-urban status has reduced substantially. However, prevalence remains high among the poor, mothers with low education, Scheduled Tribes and Muslims. Focus is needed to immunise children in hard-to-reach tribal areas, urban slums where there is a huge migrant population, and in reducing vaccine hesitancy among Muslim households with newborn children. India has much work to do to meet WHO's Immunization Agenda 2030 (IA2030) — halving zero-dose children relative to 2019. With the number of zero-dose children in 2023 (1.44 million) only about nearly reaching the 2019 level of 1.4 million, India needs greater and sustained efforts to halve this number in the next five years.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store